Arcutis Biotherapeutics (ARQT) said Thursday that data from two phase 3 studies reinforced the efficacy and safety of Zoryve cream for the treatment of mild to moderate atopic dermatitis, a form of eczema.

Zoryve, also known as roflumilast, was approved in July 2024 by the US Food and Drug Administration for the topical treatment of atopic dermatitis in adults and children.

An article in the Journal of American Medical Association Dermatology reported that Zoryve use showed significant improvements across multiple efficacy endpoints and in key secondary endpoints, including itch and 75% reduction in eczema area and severity index score in more than 40% of patients after 4 weeks, the company said.

Arcutis shares were up 1.8% in recent premarket activity.

Price: 10.59, Change: +0.19, Percent Change: +1.83